ALTRAPHARMA Invest ApS: Financial statements 2023
CVR: 34483884
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
ALTRAPHARMA Invest ApS (CVR 34483884) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -66,734 and a net result of DKK -67,116 compared with DKK -484,408 the year before. Equity in the 2023 report amounted to DKK 2,155. The solvency ratio was 1.2%.
- Gross Profit
- DKK -66,734
- Profit/Loss
- DKK -67,116
- Equity
- DKK 2,155
- Total Assets
- DKK 181,524
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -67 t. | -67 t. | 2 t. | 0 |
| 2022 | - | -172 t. | -484 t. | 69 t. | 1 |
| 2021 | - | -76 t. | -146 t. | 554 t. | 0 |
| 2020 | - | 527 t. | 407 t. | 699 t. | 0 |
| 2019 | - | 158 t. | 110 t. | 292 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout ALTRAPHARMA Invest ApS
ALTRAPHARMA Invest ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Anden teknisk rådgivning. The company was previously named ALTRAPHARMA ApS. The management consists of Marianne Thrane. The company is owned by ALTRA 14 ApS and Juniwik Business Management AB. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -88,915 and a net result of DKK -84,944 compared with DKK 86,556 the year before. Equity in the 2025 report amounted to DKK 103,766.